FAK and VEGFR-3 proteins, as well as their complexes are present in tumors and inhibition of FAK and VEGFR-3 will affect signaling in tumors and tumor microenvironments, thus both are promising therapeutic targets. The gene discussed is PTK2; the disease is neoplasm.